10-Q: Qualis Innovations Reports Q1 2024 Results: Focus Remains on SOLACE Device Development

Qualis Innovations, a clinical stage company focused on pain management solutions, releases its financial results for the quarter ended March 31, 2024, highlighting minimal operating expenses and ongoing development efforts for its SOLACE device.

Summary

• Qualis Innovations reported its financial results for the three months ended March 31, 2024.
• The company had no net revenues for both Q1 2024 and Q1 2023.
• Operating expenses decreased significantly from $79,811 in Q1 2023 to $16,160 in Q1 2024, primarily due to reduced research and development, insurance, consulting, and depreciation costs.
• The net loss for Q1 2024 was $16,160, compared to a net loss of $79,811 in Q1 2023.
• As of March 31, 2024, the company's assets totaled $90,571, primarily consisting of cash.
• Liabilities totaled $29,687, including accounts payable and a short-term note payable.
• The company issued 2,000,000 common shares for $100,000 in January 2024.
• An additional 10,000,000 common shares valued at $500,000 were issued to affiliates in settlement of a dispute in January 2024.
• The company is developing the SOLACE device, a non-invasive medical device for pain relief, and is preparing for FDA submission.
• The company has an accumulated deficit of $4,446,468 as of March 31, 2024, raising concerns about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company has reduced its losses and operating expenses, it still faces significant financial challenges, including a large accumulated deficit and the need to raise additional capital. The lack of revenue and the going concern warning also contribute to the lower sentiment score.

Positives

• The company significantly reduced its operating expenses, leading to a smaller net loss compared to the same period last year.
• The company is actively pursuing the development and regulatory approval of its SOLACE device.
• The company raised $100,000 through the issuance of common stock.
• The company settled a dispute by issuing common stock, potentially resolving a liability.

Negatives

• The company has not generated any revenue since inception.
• The company has a significant accumulated deficit, raising concerns about its financial stability.
• The company's auditors may issue an opinion about the company continuing as a going concern.
• The company's disclosure controls and procedures were not effective to enable it to accurately record, process, summarize and report certain information required to be included in the Company's periodic SEC filings within the required time periods.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional funds or generate revenues.
• The company faces competition in the medical device industry.
• The company's planned SOLACE device is subject to FDA approval, which is not guaranteed.
• The company may face challenges in manufacturing and distributing its product.
• The company's success depends on its ability to attract and retain skilled employees.

Future Outlook

The company anticipates that its current working capital, together with expected future cash flows from operations, will be insufficient to fund its operations for at least the next twelve months and intends to raise additional funds by way of a public offering or an asset sale transaction.

Industry Context

The medical device industry is highly competitive, with constant evolution and rapid scientific advances. Qualis Innovations faces competition from major pharmaceutical companies, large and small medical device companies, universities, and nonprofit research institutions.

Comparison to Industry Standards

• It is difficult to compare Qualis Innovations to industry standards due to its early stage and lack of revenue.
• Many comparable companies are larger and have established revenue streams.
• The company's success will depend on its ability to successfully develop and commercialize its SOLACE device and compete with existing pain management solutions.

Related Party Transactions

• The Company borrows funds from the Company's CEO for working capital purposes from time to time.
• In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.
• In January 2024, the Company issued a total of 10,000,000 common shares valued at $500,000 (based on the estimated fair value of the stock on the date of grant) to two affiliates in settlement of a dispute.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity financing.
• Employees are impacted by the company's financial instability and potential need for cost-cutting measures.
• Customers may benefit from the development of the SOLACE device, providing a new pain management solution.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company plans to submit its SOLACE device for FDA approval.
• The company intends to raise additional funds through a public offering or asset sale.
• The company will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future.

Key Dates

Keywords

SOLACE device, pain management, medical device, Qualis Innovations, financial results, FDA approval, operating expenses, net loss, common stock, warrants